eFFECTOR Therapeutics, Inc. (EFTR)

USD 0.0

(0.0%)

Market Cap (In USD)

941.00

Revenue (In USD)

-

Net Income (In USD)

-35.81 Million

Avg. Volume

161.89 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-17.75
PE
-
EPS
-
Beta Value
0.8
ISIN
US28202V2079
CUSIP
28202V108
CIK
1828522
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Craig R. Jalbert CIRA
Employee Count
-
Website
https://effector.com
Ipo Date
2021-03-01
Details
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.